Indicator Explainer
Everolimus
A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)
This page explains what the indicator is and how results are interpreted in general terms. Reference ranges depend on the laboratory, the method, and your own situation — no single “normal value” applies to everyone. This page is health information, not a diagnosis. For symptoms, treatment, or urgent concerns, contact a healthcare professional.
When it is tested
Source: National Cancer Institute, NCI Thesaurus 26.09d, C48387. NCI definition, reproduced without modification under CC BY 4.0. Source identity and definition checked automatically on 2026-10-20. No individual clinical interpretation or human reviewer is asserted.
Reading results
Reference intervals and interpretation depend on the laboratory, specimen, method and clinical context. This source definition is educational information; it does not establish a diagnosis, product approval or suitability for an individual.